<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016121831450N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-04-18</date_registration>
      <primary_sponsor>Vice Chancellor for research of Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Compare the effects of Avastin and Avastin combined with methylcellulose in intraocular pressure after Non-penetrating glaucoma surgery</public_title>
      <acronym></acronym>
      <scientific_title>Compare the effects of Avastin and Avastin combined with methylcellulose in intraocular pressure after Non-penetrating glaucoma surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/24732</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>glaucoma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: patients in this group will be put under general anesthesia. At first, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approximately 200 μm thick will be dissected followed by an inner concentrically 2 x 2mm scleral flap sculpted beneath the previous one. The internal flap should be dissected deep enough to have a dark reflex from the underlying choroid. The subconjunctival َAvastin group receive of 1.25 mg of bevacizumab, subconjuctival injection at the end of surgery, while the cut is advanced anteriorly, Schlemm’s canal is de-roofed. The two ostia of Schlemm’s canal are then cannulated with the specific 190 μm cannulaand Schlemm’s canal is dilated by slow and repeated injections of high-molecular-weight sodium hyaluronate . By gently pulling the inner scleral flap upwards and delicately depressing the floor of the canal and Descemet’s membrane with the tip of a cotton swab, the membrane itself is then cleaved from the cornea and the cleavage is advanced in clear cornea for approximately 1 mm, thus creating the so-called ‘trabeculo-descemetic window’ .As soon as the window is completed, the inner scleral flap is excised. The next step is the sealing of the lake, which is obtained by tightly suturing the outer scleral flap with seven 10-0 nylon stitches. High-molecular-weight sodium hyaluronate is then injected underneath the flap to fill the intrascleral space temporarily, preventing it from collapsing and scarring in the early post-operative period. Finally, the conjunctiva is sutured in place. Intervention 2: Intervention group 2: patients in this group will be put under general anesthesia. At first, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approximately 200 μm thick will be dissected followed by an inner concentrically 2 x 2mm scleral flap sculpted beneath the previous one. The internal flap should be dissected deep enough to have a dark reflex from the underlying choroid. The subconjunctival bevacizumab (ScB) group receive of 1.25 mg/ 0.3 ml of bevacizumab, subconjuctival injection at the end of surgery, while the cut is advanced anteriorly, Schlemm’s canal is de-roofed. The two ostia of Schlemm’s canal are then cannulated with the specific 190 μm cannulaand Schlemm’s canal is dilated by slow and repeated injections of high-molecular-weight sodium hyaluronate . By gently pulling the inner scleral flap upwards and delicately depressing the floor of the canal and Descemet’s membrane with the tip of a cotton swab, the membrane itself is then cleaved from the cornea and the cleavage is advanced in clear cornea for approximately 1 mm, thus creating the so-called ‘trabeculo-descemetic window’ .As soon as the window is completed, the inner scleral flap is excised. The next step is the sealing of the lake, which is obtained by tightly suturing the outer scleral flap with seven 10-0 nylon stitches. High-molecular-weight sodium hyaluronate is then injected underneath the flap to fill the intrascleral space temporarily, preventing it from collapsing and scarring in the early post-operative period. Finally, the conjunctiva is sutured in place.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>neda moghaddam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central building of the university, Golgasht street, Azadi street, Tabriz</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3657 1670</telephone>
        <email>ghmoghaddam@tabrizu.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Mostafaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central building of the university, Golgasht street, Azadi street, Tabriz</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3335 5921</telephone>
        <email>info@elibrary.tbzmed.ac.ir; dln@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:patients with open-angle glaucoma and uncontrolled IOP on maximally tolerated medical therapy with uncontrolled IOP&#13;
Exclusion criteria:Patientswith previous glaucoma and cataract surgery,previous surgery due to trauma,angle closure glaucoma, who are less than 40 years؛ Diabetes;uveitis,Collagen vascular disease,Neovascular glaucoma,end stage glaucoma</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H40.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary open-angle glaucoma      Glaucoma (primary)(residual stage):          capsular with pseudoexfoliation of lens         chronic simple         low-tension         pigmentary</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: patients in this group will be put under general anesthesia. At first, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approximately 200 μm thick will be dissected followed by an inner concentrically 2 x 2mm scleral flap sculpted beneath the previous one. The internal flap should be dissected deep enough to have a dark reflex from the underlying choroid. The subconjunctival َAvastin group receive of 1.25 mg of bevacizumab, subconjuctival injection at the end of surgery, while the cut is advanced anteriorly, Schlemm’s canal is de-roofed. The two ostia of Schlemm’s canal are then cannulated with the specific 190 μm cannulaand Schlemm’s canal is dilated by slow and repeated injections of high-molecular-weight sodium hyaluronate . By gently pulling the inner scleral flap upwards and delicately depressing the floor of the canal and Descemet’s membrane with the tip of a cotton swab, the membrane itself is then cleaved from the cornea and the cleavage is advanced in clear cornea for approximately 1 mm, thus creating the so-called ‘trabeculo-descemetic window’ .As soon as the window is completed, the inner scleral flap is excised. The next step is the sealing of the lake, which is obtained by tightly suturing the outer scleral flap with seven 10-0 nylon stitches. High-molecular-weight sodium hyaluronate is then injected underneath the flap to fill the intrascleral space temporarily, preventing it from collapsing and scarring in the early post-operative period. Finally, the conjunctiva is sutured in place.</i_keyword>
      <i_keyword>Intervention group 2: patients in this group will be put under general anesthesia. At first, a fornix-based conjunctival flap is created. Then, a 4x 4 mm outer parabolic flap, approximately 200 μm thick will be dissected followed by an inner concentrically 2 x 2mm scleral flap sculpted beneath the previous one. The internal flap should be dissected deep enough to have a dark reflex from the underlying choroid. The subconjunctival bevacizumab (ScB) group receive of 1.25 mg/ 0.3 ml of bevacizumab, subconjuctival injection at the end of surgery, while the cut is advanced anteriorly, Schlemm’s canal is de-roofed. The two ostia of Schlemm’s canal are then cannulated with the specific 190 μm cannulaand Schlemm’s canal is dilated by slow and repeated injections of high-molecular-weight sodium hyaluronate . By gently pulling the inner scleral flap upwards and delicately depressing the floor of the canal and Descemet’s membrane with the tip of a cotton swab, the membrane itself is then cleaved from the cornea and the cleavage is advanced in clear cornea for approximately 1 mm, thus creating the so-called ‘trabeculo-descemetic window’ .As soon as the window is completed, the inner scleral flap is excised. The next step is the sealing of the lake, which is obtained by tightly suturing the outer scleral flap with seven 10-0 nylon stitches. High-molecular-weight sodium hyaluronate is then injected underneath the flap to fill the intrascleral space temporarily, preventing it from collapsing and scarring in the early post-operative period. Finally, the conjunctiva is sutured in place.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intraocular pressure. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Goldmann applanation tonometry (mmHg).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Visual acuity. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Snellen charts.</sec_outcome>
      <sec_outcome>Visual field. Timepoint: Before surgery,  6 months after surgery. Method of measurement: Humphrey 24-2 SITA Standard perimetry (HFA 24-2) Or(HF30-2).</sec_outcome>
      <sec_outcome>Beleb morphology. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Moorfields Bleb Grading System.</sec_outcome>
      <sec_outcome>Endophthalmitis. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Examination slitlamp.</sec_outcome>
      <sec_outcome>Conjunctival necrosis. Timepoint: Before surgery, 1 day, 3 days, 2 weeks, 4 weeks, 3 months and 6 months after surgery. Method of measurement: Examination slitlamp.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research of Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-12-26</approval_date>
        <contact_name>Office of the Vice Chancellor for Researchof Tabriz University of Medical Sciences</contact_name>
        <contact_address>International Relations Office, No 2 Central Building, Tabriz University of Medical Sciences, University Street, Tabriz tabriz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
